Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
DAL$89.21+5.93(+7.12%)Delta vs. United: Could Falling Oil Prices Set the Stage for an Airline Stock Comeback in 2027?3:30:02 PM ETCLX$99.74+6.00(+6.40%)Clorox vs. PepsiCo: Which Dividend Stock Could Make You Richer Over the Next 10 Years?3:30:02 PM ETMU$793.75-61.18(-7.16%)Prediction: Micron Stock Will Triple in 20273:30:00 PM ETAAPL$351.68+20.04(+6.04%)Apple cuts employee AI budgets in cost-control push, Bloomberg News reports3:28:23 PM ETGOOG$289.18+10.89(+3.91%)Alphabet, Amazon, and Microsoft All Surged Today. You Can Thank the Big Blue Wave.3:25:19 PM ETARM$190.86-11.82(-5.83%)Arm Stock Has Crashed 37%. Is It a Better Buy Than Qualcomm?3:17:42 PM ETVZ$46.28+1.05(+2.32%)Verizon announces pricing terms of its tender offers for five series of notes3:16:40 PM ETCL$98.97+3.37(+3.53%)Here's Why Dividend Kings Coca-Cola, Procter & Gamble, and Colgate-Palmolive Are Hitting 52-Week Highs Following Midterm Election Results3:15:02 PM ETPFE$30.73+0.75(+2.50%)Pfizer Q3: The Street Is Pricing In Too Much Deceleration For This 5.7% Yield3:10:30 PM ETSHOP$153.22+10.51(+7.36%)Shopify Could Be the Best Growth Stock to Buy With $1,000 in November3:10:00 PM ETMSFT$556.96+36.18(+6.95%)Microsoft and Amazon combine for a $400 billion market-cap boost — and these factors show why3:04:00 PM ETQCOM$167.37+2.94(+1.79%)Bull v. Bear: QCOM Historic SPCX Deal Sets Sky-High Bar Beyond Mobile3:00:00 PM ETMU$793.75-61.18(-7.16%)Why Micron Stock Is Falling Today2:59:01 PM ETQCOM$167.37+2.94(+1.79%)Why SpaceX Stock Is Down Today2:55:01 PM ETSWKS$82.74-2.55(-2.99%)Skyworks Is Still Up 31% This Year: Is SWKS Stock Topping Out and Breaking Down?2:55:00 PM ETMCD$279.47+16.40(+6.23%)McDonald's to add new value bundles next year2:53:04 PM ETALC$77.51+5.14(+7.10%)Ophthalmic Equipment Market to Reach US$ 30.5 Bn by 2031, Growing at 7.5% CAGR: Wissen Research The global ophthalmic equipment market is valued at USD 21.2 billion in 2026 and is projected to reach USD 30.5 billion by 2031, growing at a CAGR of ...2:52:00 PM ETMSFT$556.96+36.18(+6.95%)PeoplePath Releases New Corporate Alumni Benchmark Data Revealing Multi-Million Dollar Revenue and Recruitment Impact2:40:00 PM ETAAPL$351.68+20.04(+6.04%)Hyperscalers and Apple surge after election results remove investor uncertainty2:37:43 PM ETAAPL$351.68+20.04(+6.04%)Apple, Tesla Supplier Is Taking on 3M: Here's What Investors Should Know2:34:09 PM ETANET$178.34+8.37(+4.92%)Own an AI or Tech ETF? Arista's Big Quarter Just Paid Off2:33:50 PM ETGOOG$289.18+10.89(+3.91%)Google Is Telling Schools to Take Its AI or Lose Its Search Engine2:32:16 PM ETAMD$481.63-2.20(-0.45%)AMD's "Double Black Diamond Ski Run:" Do Earnings Show Steeper Rally Ahead?2:30:20 PM ETGOOG$289.18+10.89(+3.91%)DuckDuckGo pitches itself to schools amid backlash over Google's AI policy2:29:52 PM ET

NVCT · NASDAQ

Nuvectis Pharma, Inc.

$18.90 -0.47 (-2.43%)

Company overview

Nuvectis Pharma, Inc. is a biopharmaceutical company focused on developing precision medicines for treating serious unmet medical needs in oncology. The company develops NXP800, a novel heat shock factor 1 pathway inhibitor for treating various cancers, and NXP900, a small molecule drug candidate that inhibits the proto-oncogene c-Src and YES1 kinases. Founded in 2020, the company is based in Fort Lee, New Jersey.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$617M
Employees
13
Headquarters
Fort Lee, NJ
Website
nuvectis.com
CEO
Ron Bentsur
Listed
February 4, 2022
P/E
-14.12
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
$0.00
Operating income
-$28.3M
EBITDA
-$28.3M
Net income
-$27.2M
EPS
-$1.31
Total assets
$25.4M
Total debt
$0.00
Earnings yield
-7.08%

Price chart

7.5913.2218.8524.4830.11
NVCT 1D NASDAQ O19.18H19.83L18.82C19.34+0.16 (+0.83%)Vol143.08K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
NVCTNuvectis Pharma, Inc. Stock news Nuvectis Pharma Q3 Earnings Call Highlights MarketBeat
NVCTNuvectis Pharma, Inc. Press release Nuvectis Pharma Reports Third Quarter 2026 Financial Results and Business Highlights GlobeNewswire
NVCTNuvectis Pharma, Inc. Press release Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026 GlobeNewswire
NVCTNuvectis Pharma, Inc. Press release Nuvectis Reports Positive Data from NXP200 Phase 1b Study Demonstrating Durable Responses, Including Complete Responses, in BRAF V600-mutated Recurrent or Progressive Gliomas GlobeNewswire
NVCTNuvectis Pharma, Inc. Stock news Nuvectis Pharma, Inc. (NASDAQ:NVCT) Stock Has Consensus Target Price of $36.25 According to Brokerages Defense World
NVCTNuvectis Pharma, Inc. Press release Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma GlobeNewswire
NVCTNuvectis Pharma, Inc. Stock news BlackRock Inc. Acquires New Stake in Nuvectis Pharma, Inc. $NVCT Defense World
NVCTNuvectis Pharma, Inc. Press release Nuvectis Pharma To Participate in Upcoming Investor Conferences GlobeNewswire
NVCTNuvectis Pharma, Inc. Stock news This Brinker International Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Benzinga
NVCTNuvectis Pharma, Inc. Stock news Nuvectis Stock Surges Around 97% in 3 Months: Here's Why Zacks Investment Research
NVCTNuvectis Pharma, Inc. Press release Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights GlobeNewswire
NVCTNuvectis Pharma, Inc. Press release Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors GlobeNewswire
NVCTNuvectis Pharma, Inc. Press release Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors GlobeNewswire
RYAAY Stock news Ryanair Posts Weak Q1 Results, Joins HDFC Bank And Other Big Stocks Moving Lower In Monday's Pre-Market Session Benzinga
NVCTNuvectis Pharma, Inc. Press release StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data Newsfile Corp
NVCTNuvectis Pharma, Inc. Stock news Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High? Zacks Investment Research
IBM Stock news IBM To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Monday Benzinga
NVCTNuvectis Pharma, Inc. Stock news Wall Street Analysts Think Nuvectis Pharma (NVCT) Could Surge 57%: Read This Before Placing a Bet Zacks Investment Research
NVCTNuvectis Pharma, Inc. Press release Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ GlobeNewswire
NVCTNuvectis Pharma, Inc. Stock news Wall Street Analysts Believe Nuvectis Pharma (NVCT) Could Rally 62.5%: Here's is How to Trade Zacks Investment Research
See more
FAQ

Questions about Nuvectis Pharma, Inc.

What does Nuvectis Pharma, Inc. do?
Nuvectis Pharma, Inc. is a biopharmaceutical company focused on developing precision medicines for treating serious unmet medical needs in oncology. The company develops NXP800, a novel heat shock factor 1 pathway inhibitor for treating various cancers, and NXP900, a small molecule drug candidate that inhibits the proto-oncogene c-Src and YES1 kinases. Founded in 2020, the company is based in Fort Lee, New Jersey.
What is NVCT's market cap?
Nuvectis Pharma, Inc. (NVCT) is a listed stock with a live quote. The latest market cap on this page is $617M.
Where is Nuvectis Pharma, Inc. headquartered?
Nuvectis Pharma, Inc. is headquartered in Fort Lee, NJ.
How do I get NVCT news from the API?
Call GET /v1/news?tickers=NVCT. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does NVCT news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for NVCT, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the NVCT price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs